The aim of the study was to investigate the possible effects of complex therapy, including Hepadif, Ezetrol and Fosinopril on the blood lipid profile, and the degree of insulin resistance in patients with comorbid course of NASH and hypertension of II stage. Materials and methods. Sixty patients with NASH with comorbid hypertension of II stage and obesity of I type were included in the study. To determine the effectiveness of treatment, 2 groups of patients were formed. The control group (30 people) received a hypocaloric diet, Metformin, Essentiale, Atorvastatin (Atocor), Enalapril maleate for 30 days. The main group (30 people) received a hypocaloric diet, Metformin, Hepadif, Ezetrol, Fosinopril for 30 days. Results and discussion. The blood lipid spectrum was studied by the content of total cholesterol, triacylglycerols, low-density lipoproteins and high density lipoproteins, and calculated the atherogenic index according to the formula. The state of carbohydrate metabolism was determined by the level of fasting glycemia and 2 hours after glucose loading (glucose tolerant test), the content of insulin in the blood was checked by the method of immunoassay analysis, the content of glycosylated hemoglobin in blood. The degree of insulin resistance was determined by the value of the body mass index: body weight (kg)/height(m2); index HOMA-IR. Conclusions. The study showed that complex therapy consisting of Hepatif, Ezetrol and Fosinopril is effective in the treatment of non-alcoholic steatohepatitis in the background of hypertension of II stage and metabolic syndrome for the correction of the main clinical and biochemical syndromes of the main and concomitant diseases, the lipid spectrum of blood with the elimination of hyper- and dyslipidemia. It also decreases the atherogenic index, potentiates hypoglycemic effects of metformin, produces antioxidant and membrane-stabilizing effects.

Keywords: non-alcoholic steatohepatitis, hypertonic disease, obesity, lipid blood spectrum, insulin resistance

Full text: PDF (Ukr) 207K

1. Babak O.Ya., Kolesnikova E.V., Syitnik K.A. Profilakticheskie meropriyatiya pri nealkogolnoy zhirovoy bolezni pecheni: suschestvuet li sposob snizit risk razvitiya zabolevaniya? [Preventive measures for non-alcoholic fatty liver disease: is there a way to reduce the risk of the disease?]. Suchasna gastroenterol. 2013; 3 (71): 103-9. [Russian]
2. Bueverov AO, Bogomolov PO. Nealkogol'naya zhirovaya bolezn' pecheni: obosnovanie patogeneticheskoy terapii [Non-alcoholic fatty liver disease: rationale for pathogenetic therapy]. Klinicheskie perspektivy v gastroenterologii, gepatologii. 2009; 1: 3-9. [Russian]
3. Chekman NV, Kharchenko HA, Anokhina GA. Kliniko-farmakolohichni vlastyvosti ta osoblyvosti zastosuvannia kombinovanoho hepatoprotektornoho preparatu “Hepadyf” yak preparatu terapii suprovodu pry pryiomi statyniv [Clinical and pharmacological properties and peculiarities of the use of the combined hepatoprotective drug "Hepadif" as a preparation of maintenance therapy in the administration of statins]. Suchasna hastroenterol. 2010; 4: 77-81. [Ukrainian]
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-44. https://www.ncbi.nlm.nih.gov/pubmed/23507799. https://doi.org/10.1038/nrgastro.2013.41
5. Drapkina OM, Kostyukevich MV. Metabolicheskiy sindrom: problema gepatotoksichnosti pri lechenii statinami. Ateroskleroz i dislipidemii. [Metabolic syndrome: the problem of hepatotoxicity in the treatment by statins]. Ateroskleroz i dislipidemii. 2013; 3 (10): 45–51. [Russian].
6. Ekstedt M, Franzén LE, Mathiesen UL. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007; 47 (1): 135-41. https://www.ncbi.nlm.nih.gov/pubmed/17400325. https://doi.org/10.1016/j.jhep.2007.02.013
7. Georgescu EF. Angiotensin receptor blockers in the treatmentof NASH/NAFLD: couldtheybe a first-classoption? Adv Ther. 2008; 25 (11): 1141-74.
8. Gubergrits NB, Golub EYu. Effektivnost' gepadifa v lechenii nealkogol'nogo steatogepatita, razvivshegosya vsledstvie abdomіnal'nogo ishemicheskogo sindroma [The efficiency of hepadif in the treatment of non-alcoholic steatohepatitis, which developed as a result of abdominal ischemic syndrome]. Klіn ta eksperiment patologіya. 2008; 7 (3): 142-6. [Russian]
9. Khukhlina OS, Mandryk OIe. Nealkoholnyi steatohepatyt ta hipertonichna khvoroba: osoblyvosti komorbidnoho perebihu, optymizovani pidkhody do likuvannia: Monohraffia [Non-alcoholic steatohepatitis and hypertension: features of the comorbid course, optimized approaches to treatment: Monograph] Chernivtsi, Ukraine, 2014. 204 p.
10. Kolesnikova EV. Nealkogol'naya zhirovaya bolezn' pecheni i arterial'naya gipertenziya: chego my dostigli v ponimanii problem [Non-alcoholic fatty liver disease and arterial hypertension: what have we achieved in understanding the problem]. Ukrainskyi medychnyi chasopys. 2014; 3 (101): 61-6. [Russian]
11. Kowdley KV. Advances in the diagnosis and treatment of nonalcoholic steatohepatitis. Gastroenterol. Hepatol. (NY). 2014; 10 (3): 184-6. https://www.ncbi.nlm.nih.gov/pmc/articles/4014051
12. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2010; 3 (2): 121-37. https://www.ncbi.nlm.nih.gov/pubmed/21180596. https://www.ncbi.nlm.nih.gov/pmc/articles/3002571. https://doi.org/10.1177/1756283X09359964
13. Latea L, Negrea S, Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. Australas Med J. 2013; 6 (6): 325-30. https://doi.org/10.4066/AMJ.2013.1648
14. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012; 55 (4): 885-904. https://www.ncbi.nlm.nih.gov/pubmed/22278337. https://doi.org/10.1007/s00125-011-2446-4
15. Sokolova NA. Issledovanie antiaterogennoy effektivnosti statinovi kombinatsii statina c ingibitorom adsorbtsii kholesterina ezetimibom u bol'nykh s karotidnym aterosklerozom [The study of the antiatherogenic effectiveness of statins and the combination of statin with an inhibitor of cholesterol adsorption with ezetimibe in patients with carotid atherosclerosis]: avtoref. dis. … kand. med. nauk, Abstr. PhDr. (Med.).Moskva; 2010. 28 s. [Russian]